{"pmid":32388537,"title":"Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).","text":["Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).","Signal Transduct Target Ther","Mengist, Hylemariam Mihiretie","Fan, Xiaojiao","Jin, Tengchuan","32388537"],"journal":"Signal Transduct Target Ther","authors":["Mengist, Hylemariam Mihiretie","Fan, Xiaojiao","Jin, Tengchuan"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388537","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41392-020-0178-y","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892587491328,"score":9.490897,"similar":[{"pmid":32198291,"pmcid":"PMC7164518","title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors.","text":["Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (M(pro), also called 3CL(pro)) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 M(pro) and its complex with an alpha-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro) The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.","Science","Zhang, Linlin","Lin, Daizong","Sun, Xinyuanyuan","Curth, Ute","Drosten, Christian","Sauerhering, Lucie","Becker, Stephan","Rox, Katharina","Hilgenfeld, Rolf","32198291"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (M(pro), also called 3CL(pro)) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 M(pro) and its complex with an alpha-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro) The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route."],"journal":"Science","authors":["Zhang, Linlin","Lin, Daizong","Sun, Xinyuanyuan","Curth, Ute","Drosten, Christian","Sauerhering, Lucie","Becker, Stephan","Rox, Katharina","Hilgenfeld, Rolf"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198291","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1126/science.abb3405","e_drugs":["Pyridones","Amides"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490109165568,"score":103.45322},{"pmid":32313296,"pmcid":"PMC7165110","title":"Identification of Potential Binders of the Main Protease 3CL(pro) of the COVID-19 via Structure-Based Ligand Design and Molecular Modeling.","text":["Identification of Potential Binders of the Main Protease 3CL(pro) of the COVID-19 via Structure-Based Ligand Design and Molecular Modeling.","We have applied a computational strategy, using a combination of virtual screening, docking and molecular dynamics techniques, aimed at identifying possible lead compounds for the non-covalent inhibition of the main protease 3CL(pro) of the SARS-CoV2 Coronavirus. Based on the X-ray structure (PDB code: 6LU7), ligands were generated using a multimodal structure-based design and then docked to the monomer in the active state. Docking calculations show that ligand-binding is strikingly similar in SARS-CoV and SARS-CoV2 main proteases. The most potent docked ligands are found to share a common binding pattern with aromatic moieties connected by rotatable bonds in a pseudo-linear arrangement.","Chem Phys Lett","Macchiagodena, Marina","Pagliai, Marco","Procacci, Piero","32313296"],"abstract":["We have applied a computational strategy, using a combination of virtual screening, docking and molecular dynamics techniques, aimed at identifying possible lead compounds for the non-covalent inhibition of the main protease 3CL(pro) of the SARS-CoV2 Coronavirus. Based on the X-ray structure (PDB code: 6LU7), ligands were generated using a multimodal structure-based design and then docked to the monomer in the active state. Docking calculations show that ligand-binding is strikingly similar in SARS-CoV and SARS-CoV2 main proteases. The most potent docked ligands are found to share a common binding pattern with aromatic moieties connected by rotatable bonds in a pseudo-linear arrangement."],"journal":"Chem Phys Lett","authors":["Macchiagodena, Marina","Pagliai, Marco","Procacci, Piero"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313296","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cplett.2020.137489","keywords":["3cl-pro","3cl-pro inhibitor","binding affinity","covid-19","coronavirus","coronavirus main protease","molecular docking","molecular dynamics","sars-cov2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493564223489,"score":79.441666},{"pmid":32321856,"pmcid":"PMC7179937","title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.","text":["Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.","SARS-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak. The main protease (M(pro)) of SARS-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting M(pro) Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The X-ray crystal structures of SARS-CoV-2 M(pro) in complex with 11a or 11b, both determined at 1.5 A resolution, showed that the aldehyde groups of 11a and 11b are covalently bound to Cys145 of M(pro) Both compounds showed good PK properties in vivo, and 11a also exhibited low toxicity, suggesting that these compounds are promising drug candidates.","Science","Dai, Wenhao","Zhang, Bing","Su, Haixia","Li, Jian","Zhao, Yao","Xie, Xiong","Jin, Zhenming","Liu, Fengjiang","Li, Chunpu","Li, You","Bai, Fang","Wang, Haofeng","Cheng, Xi","Cen, Xiaobo","Hu, Shulei","Yang, Xiuna","Wang, Jiang","Liu, Xiang","Xiao, Gengfu","Jiang, Hualiang","Rao, Zihe","Zhang, Lei-Ke","Xu, Yechun","Yang, Haitao","Liu, Hong","32321856"],"abstract":["SARS-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak. The main protease (M(pro)) of SARS-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting M(pro) Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The X-ray crystal structures of SARS-CoV-2 M(pro) in complex with 11a or 11b, both determined at 1.5 A resolution, showed that the aldehyde groups of 11a and 11b are covalently bound to Cys145 of M(pro) Both compounds showed good PK properties in vivo, and 11a also exhibited low toxicity, suggesting that these compounds are promising drug candidates."],"journal":"Science","authors":["Dai, Wenhao","Zhang, Bing","Su, Haixia","Li, Jian","Zhao, Yao","Xie, Xiong","Jin, Zhenming","Liu, Fengjiang","Li, Chunpu","Li, You","Bai, Fang","Wang, Haofeng","Cheng, Xi","Cen, Xiaobo","Hu, Shulei","Yang, Xiuna","Wang, Jiang","Liu, Xiang","Xiao, Gengfu","Jiang, Hualiang","Rao, Zihe","Zhang, Lei-Ke","Xu, Yechun","Yang, Haitao","Liu, Hong"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321856","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1126/science.abb4489","locations":["vivo"],"e_drugs":["Aldehydes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493851533312,"score":73.288605},{"pmid":32471205,"title":"Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.","text":["Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.","Since the outbreak of the COVID-19 pandemic in December 2019 and its rapid spread worldwide, the scientific community has been under pressure to react and make progress in the development of an effective treatment against the virus responsible for the disease. Here, we implement an original virtual screening (VS) protocol for repositioning approved drugs in order to predict which of them could inhibit the main protease of the virus (M-pro), a key target for antiviral drugs given its essential role in the virus' replication. Two different libraries of approved drugs were docked against the structure of M-pro using Glide, FRED and AutoDock Vina, and only the equivalent high affinity binding modes predicted simultaneously by the three docking programs were considered to correspond to bioactive poses. In this way, we took advantage of the three sampling algorithms to generate hypothetic binding modes without relying on a single scoring function to rank the results. Seven possible SARS-CoV-2 M-pro inhibitors were predicted using this approach: Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate. Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3.97 and 11.90% M-pro inhibition at 50 microM, respectively.","Int J Mol Sci","Gimeno, Aleix","Mestres-Truyol, Julia","Ojeda-Montes, Maria Jose","Macip, Guillem","Saldivar-Espinoza, Bryan","Cereto-Massague, Adria","Pujadas, Gerard","Garcia-Vallve, Santiago","32471205"],"abstract":["Since the outbreak of the COVID-19 pandemic in December 2019 and its rapid spread worldwide, the scientific community has been under pressure to react and make progress in the development of an effective treatment against the virus responsible for the disease. Here, we implement an original virtual screening (VS) protocol for repositioning approved drugs in order to predict which of them could inhibit the main protease of the virus (M-pro), a key target for antiviral drugs given its essential role in the virus' replication. Two different libraries of approved drugs were docked against the structure of M-pro using Glide, FRED and AutoDock Vina, and only the equivalent high affinity binding modes predicted simultaneously by the three docking programs were considered to correspond to bioactive poses. In this way, we took advantage of the three sampling algorithms to generate hypothetic binding modes without relying on a single scoring function to rank the results. Seven possible SARS-CoV-2 M-pro inhibitors were predicted using this approach: Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate. Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3.97 and 11.90% M-pro inhibition at 50 microM, respectively."],"journal":"Int J Mol Sci","authors":["Gimeno, Aleix","Mestres-Truyol, Julia","Ojeda-Montes, Maria Jose","Macip, Guillem","Saldivar-Espinoza, Bryan","Cereto-Massague, Adria","Pujadas, Gerard","Garcia-Vallve, Santiago"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471205","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113793","keywords":["2019-ncov","3cl-pro","covid-19","m-pro","sars coronavirus","sars-cov-2","chymotrypsin-like protease"],"locations":["FRED","Perampanel","Carprofen","Trovafloxacin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193348702208,"score":65.65834},{"pmid":32382072,"title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.","text":["Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.","The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M(pro)). Here, the X-ray crystal structure of M(pro) in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 muM) and is a promising lead compound to develop new antiviral treatment for COVID-19.","Nat Struct Mol Biol","Jin, Zhenming","Zhao, Yao","Sun, Yuan","Zhang, Bing","Wang, Haofeng","Wu, Yan","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Du, Xiaoyu","Duan, Yinkai","Yu, Jing","Yang, Xiaobao","Yang, Xiuna","Yang, Kailin","Liu, Xiang","Guddat, Luke W","Xiao, Gengfu","Zhang, Leike","Yang, Haitao","Rao, Zihe","32382072"],"abstract":["The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M(pro)). Here, the X-ray crystal structure of M(pro) in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 muM) and is a promising lead compound to develop new antiviral treatment for COVID-19."],"journal":"Nat Struct Mol Biol","authors":["Jin, Zhenming","Zhao, Yao","Sun, Yuan","Zhang, Bing","Wang, Haofeng","Wu, Yan","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Du, Xiaoyu","Duan, Yinkai","Yu, Jing","Yang, Xiaobao","Yang, Xiuna","Yang, Kailin","Liu, Xiang","Guddat, Luke W","Xiao, Gengfu","Zhang, Leike","Yang, Haitao","Rao, Zihe"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382072","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41594-020-0440-6","e_drugs":["1-hexylcarbamoyl-5-fluorouracil"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666419683280027650,"score":62.432022}]}